Development of dexamethasone-loaded mixed polymeric micelles for nasal delivery

Our study aimed to formulate a novel dexamethasone (DXM)-loaded, mixed polymeric micelle-based drug delivery system, focusing on the auspicious nose-to-brain pathway, as a key delivery route to treat central nervous system (CNS) associated diseases. Polymeric micelles might be a solution to deliver drugs to the place of action compared to conventional formulations.


The mixed micellar formulation enhanced solubility of dexamethasone.

Dexamethasone-loaded mixed micelles provided rapid drug release.

The mixed micellar formulation is applicable for the nasal administration.

The mixed micellar formulation showed higher permeability across blood-brain-barrier lipids.

Due to low Z-average (89.92 ± 2.7 nm), a polydispersity index of 0.216 ± 0.014 and high surface polarity (52.23%), a significant increase in water solubility (14-fold) was experienced. This increase resulted in favourable dissolution profile at nasal and axonal conditions with high in vitro permeability value (14.6×10−6 cm/s) on polar brain (porcine) lipid extract.

Modified Side-bi-side® type diffusion study confirmed rapid and efficient passive diffusion through the nasal mucosa contributed by strong mucoadhesive properties. The final formulation met all the requirements of a nasal drug delivery system with rapid onset of action, meaning DXM can reach the CNS and there it can exert its beneficial effects in pathological conditions.

Read the article here

Article information: Bence Sipos, Ildikó Csóka, Mária Budai-Szűcs, Gábor Kozma, Dániel Berkesi, Zoltán Kónya, György Tibor Balogh, Gábor Katona, Development of dexamethasone-loaded mixed polymeric micelles for nasal delivery, European Journal of Pharmaceutical Sciences, Volume 166, 2021.

You might also like